Navigation überspringen
Universitätsbibliothek Heidelberg

disk Markieren   Persönliche Notiz
Drucker
Andere Formate
Exportieren/Zitieren
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Scheiner, Bernhard [VerfasserIn]   i
 Roessler, Daniel [VerfasserIn]   i
 Phen, Samuel [VerfasserIn]   i
 Lim, Mir [VerfasserIn]   i
 Pomej, Katharina [VerfasserIn]   i
 Pressiani, Tiziana [VerfasserIn]   i
 Cammarota, Antonella [VerfasserIn]   i
 Fründt, Thorben Wilhelm [VerfasserIn]   i
 Felden, Johann von [VerfasserIn]   i
 Schulze, Kornelius [VerfasserIn]   i
 Himmelsbach, Vera [VerfasserIn]   i
 Finkelmeier, Fabian [VerfasserIn]   i
 Deibel, Rudolf Ansgar [VerfasserIn]   i
 Siebenhüner, Alexander [VerfasserIn]   i
 Shmanko, Kateryna [VerfasserIn]   i
 Radu, Pompilia [VerfasserIn]   i
 Schwacha-Eipper, Birgit [VerfasserIn]   i
 Ebert, Matthias [VerfasserIn]   i
 Teufel, Andreas [VerfasserIn]   i
 Djanani, Angela [VerfasserIn]   i
 Hucke, Florian [VerfasserIn]   i
 Balcar, Lorenz [VerfasserIn]   i
 Philipp, Alexander B. [VerfasserIn]   i
 Hsiehchen, David [VerfasserIn]   i
 Venerito, Marino [VerfasserIn]   i
 Sinner, Friedrich [VerfasserIn]   i
 Trauner, Michael [VerfasserIn]   i
 D'Alessio, Antonio [VerfasserIn]   i
 Fulgenzi, Claudia A. M. [VerfasserIn]   i
 Pinato, David J. [VerfasserIn]   i
 Peck-Radosavljevic, Markus [VerfasserIn]   i
 Dufour, Jean-François [VerfasserIn]   i
 Weinmann, Arndt [VerfasserIn]   i
 Kremer, Andreas [VerfasserIn]   i
 Singal, Amit G. [VerfasserIn]   i
 Toni, Enrico de [VerfasserIn]   i
 Rimassa, Lorenza [VerfasserIn]   i
 Pinter, Matthias [VerfasserIn]   i
Titel:Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
Verf.angabe:Bernhard Scheiner, Daniel Roessler, Samuel Phen, Mir Lim, Katharina Pomej, Tiziana Pressiani, Antonella Cammarota, Thorben W. Fründt, Johann von Felden, Kornelius Schulze, Vera Himmelsbach, Fabian Finkelmeier, Ansgar Deibel, Alexander R. Siebenhüner, Kateryna Shmanko, Pompilia Radu, Birgit Schwacha-Eipper, Matthias P. Ebert, Andreas Teufel, Angela Djanani, Florian Hucke, Lorenz Balcar, Alexander B. Philipp, David Hsiehchen, Marino Venerito, Friedrich Sinner, Michael Trauner, Antonio D'Alessio, Claudia A. M. Fulgenzi, David J. Pinato, Markus Peck-Radosavljevic, Jean-François Dufour, Arndt Weinmann, Andreas E. Kremer, Amit G. Singal, Enrico N. De Toni, Lorenza Rimassa, Matthias Pinter
E-Jahr:2023
Jahr:January 2023
Umfang:8 S.
Fussnoten:Online verfügbar: 27. Oktober 2022, Artikelversion: 2. Januar 2023
Titel Quelle:Enthalten in: JHEP reports
Ort Quelle:Amsterdam : Elsevier, 2019
Jahr Quelle:2023
Band/Heft Quelle:5(2023), 1 vom: Jan., Artikel-ID 100620
ISSN Quelle:2589-5559
Abstract:Background & Aims - We investigated the efficacy and safety of immune checkpoint inhibitor (ICI) rechallenge in patients with hepatocellular carcinoma (HCC) who received ICI-based therapies in a previous systemic line. - Methods - In this international, retrospective multicenter study, patients with HCC who received at least two lines of ICI-based therapies (ICI-1, ICI-2) at 14 institutions were eligible. The main outcomes included best overall response and treatment-related adverse events. - Results - Of 994 ICI-treated patients screened, a total of 58 patients (male, n = 41; 71%) with a mean age of 65.0±9.0 years were included. Median systemic treatment lines of ICI-1 and ICI-2 were 1 (range, 1-4) and 3 (range, 2-9), respectively. ICI-based therapies used at ICI-1 and ICI-2 included ICI alone (ICI-1, n = 26, 45%; ICI-2, n = 4, 7%), dual ICI regimens (n = 1, 2%; n = 12, 21%), or ICI combined with targeted therapies/anti-VEGF (n = 31, 53%; n = 42, 72%). Most patients discontinued ICI-1 due to progression (n = 52, 90%). Objective response rate was 22% at ICI-1 and 26% at ICI-2. Responses at ICI-2 were also seen in patients who had progressive disease as best overall response at ICI-1 (n = 11/21; 52%). Median time-to-progression at ICI-1 and ICI-2 was 5.4 (95% CI 3.0-7.7) months and 5.2 (95% CI 3.3-7.0) months, respectively. Treatment-related adverse events of grade 3-4 at ICI-1 and ICI-2 were observed in 9 (16%) and 10 (17%) patients, respectively. - Conclusions - ICI rechallenge was safe and resulted in a treatment benefit in a meaningful proportion of patients with HCC. These data provide a rationale for investigating ICI-based regimens in patients who progressed on first-line immunotherapy in prospective trials. - Impact and implications - Therapeutic sequencing after first-line immune checkpoint inhibitor (ICI)-based therapy for advanced hepatocellular carcinoma (HCC) remains a challenge as no available second-line treatment options have been studied in immunotherapy-pretreated patients. Particularly, the role of ICI rechallenge in patients with HCC is unclear, as data from prospective trials are lacking. We investigated the efficacy and safety of ICI-based regimens in patients with HCC pretreated with immunotherapy in a retrospective, international, multicenter study. Our data provide the rationale for prospective trials investigating the role of ICI-based regimens in patients who have progressed on first-line immunotherapy.
DOI:doi:10.1016/j.jhepr.2022.100620
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Resolving-System: https://dx.doi.org/10.1016/j.jhepr.2022.100620
 DOI: https://doi.org/10.1016/j.jhepr.2022.100620
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1860069207
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69128590   QR-Code
zum Seitenanfang

© Universitätsbibliothek HeidelbergMailImpressum / Datenschutz   Design